Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Medical Science Research Institute, Soonchunhyang University Seoul Hospital, Seoul, Korea.
Cell Prolif. 2018 Oct;51(5):e12463. doi: 10.1111/cpr.12463. Epub 2018 May 2.
The purpose of this study was to explore the effectiveness of concurrent GRP78 overexpression combined with Cripto on hMSC proliferation and migration both in vitro and in vivo. Specifically, we explored whether the treatment enhances effectiveness of hMSC transplantation in ischaemic tissue.
Human MSCs obtained from human adipose tissue were cultured in α-minimum essential medium (Hyclone, Logan, UT, USA) supplemented with 10% (v/v) foetal bovine serum (Hyclone), 100 U mL penicillin and 100 μg mL streptomycin. Murine hindlimb ischaemic model was generated with 8-week-old male nude BALB/c mice (Biogenomics, Seoul, Korea) maintained under a 12-h light/dark cycle following the established protocol with minor modification. Cellular injection was performed no later than 3 hour after surgery. Lipofectamine transfection, single-cell cultivation assay, transwell assay, scratch wound-healing migration assay, immunohistochemistry and western blotting assays were performed.
Overexpression of GRP78 along with Cripto enhanced hMSC proliferation, migration and invasion. It increased interaction of surface GRP78 receptor with Cripto via JAK2/STAT3 pathway. We confirmed our proposed mechanism by showing that treatment with GRP78 antibody blocks the enhancement in vitro. In vivo, we observed that Cripto induced by the hypoxic environment in hindlimb ischaemic model interacts with the overexpressed GRP78 and increases hMSC proliferation, migration and invasion potentials as well as angiogenesis around transplanted ischaemic site via cytokine secretions.
These results demonstrate supporting evidences that GRP78-Cripto combination technique offers novel strategy to enhance MSC proliferation, migration and invasion potentials as well as angiogenesis around ischaemic site, ultimately facilitating MSC-based transplantation therapy in ischaemic conditions.
本研究旨在探讨同时过表达葡萄糖调节蛋白 78(GRP78)和 Cripto 对人骨髓间充质干细胞(hMSC)增殖和迁移的体内外作用。具体而言,我们探讨了这种治疗方法是否能增强 hMSC 在缺血组织中的移植效果。
从人脂肪组织中培养人骨髓间充质干细胞,在α-最小必需培养基(Hyclone,Logan,UT,美国)中培养,添加 10%(v/v)胎牛血清(Hyclone)、100U mL 青霉素和 100μg mL 链霉素。根据已建立的方案,对 8 周龄雄性裸鼠 BALB/c (Biogenomics,首尔,韩国)进行后肢缺血模型的生成,有轻微修改。手术后不迟于 3 小时进行细胞注射。进行脂质体转染、单细胞培养试验、Transwell 测定、划痕愈合迁移试验、免疫组织化学和 Western blot 测定。
GRP78 与 Cripto 的共表达增强了 hMSC 的增殖、迁移和侵袭。它通过 JAK2/STAT3 通路增强了表面 GRP78 受体与 Cripto 的相互作用。通过显示 GRP78 抗体的治疗阻断了体外的增强,我们证实了我们提出的机制。在体内,我们观察到,后肢缺血模型缺氧环境诱导的 Cripto 与过表达的 GRP78 相互作用,通过细胞因子分泌增加移植缺血部位周围的 hMSC 增殖、迁移和侵袭潜能以及血管生成。
这些结果提供了支持性证据,表明 GRP78-Cripto 联合技术为增强 MSC 增殖、迁移和侵袭潜能以及缺血部位周围的血管生成提供了新的策略,最终促进了 MSC 为基础的缺血条件下的移植治疗。